{"DataElement":{"publicId":"6741255","version":"1","preferredName":"Cutaneous T-cell Lymphoma Response in Lymph Nodes Category","preferredDefinition":"Response category that describes the disease involvement in lymph nodes based on staging and classification criteria for cutaneous T-cell lymphoma (CTCL).","longName":"CTCL_NODES_SCR_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6741243","version":"1","preferredName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Global Response in Lymph Nodes","preferredDefinition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma._Criteria for the response to treatment in lymph nodes, as a component of global response.","longName":"6741233v1.0:6741241v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"6741233","version":"1","preferredName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","preferredDefinition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","longName":"C3467","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","conceptCode":"C3467","definition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A32B7-C39E-1131-E053-F662850AA707","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6741241","version":"1","preferredName":"Global Response in Lymph Nodes","preferredDefinition":"Criteria for the response to treatment in lymph nodes, as a component of global response.","longName":"C159957","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Response in Lymph Nodes","conceptCode":"C159957","definition":"Criteria for the response to treatment in lymph nodes, as a component of global response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A32B7-C3D8-1131-E053-F662850AA707","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A32B7-C3E9-1131-E053-F662850AA707","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"COOPERM","dateModified":"2019-05-07","changeDescription":"Created for NCI-INC0370865: 19C0076 qns curation request. 4.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6741213","version":"1","preferredName":"Global Response in Lymph Nodes Category","preferredDefinition":"Criteria for the response to treatment in lymph nodes, as a component of global response._A grouping of items based on some commonality or by user defined characteristics.","longName":"GR_NODE_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CR","valueDescription":"Global Complete Response in Lymph Nodes","ValueMeaning":{"publicId":"6741214","version":"1","preferredName":"Global Complete Response in Lymph Nodes","longName":"6741214","preferredDefinition":"All lymph nodes are now 1.5 cm or less in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph nodes that were N3 classification and 1.5 cm or less in their long axis and more than 1 cm in their short axis at baseline, must now be 1 cm or less in their short axis or biopsy negative for lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Complete Response in Lymph Nodes","conceptCode":"C159958","definition":"All lymph nodes are now 1.5 cm or less in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph nodes that were N3 classification and 1.5 cm or less in their long axis and more than 1 cm in their short axis at baseline, must now be 1 cm or less in their short axis or biopsy negative for lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-94AC-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8839716C-94C5-2EBA-E053-F662850AA2E9","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"PD","valueDescription":"Global Progressive Disease in Lymph Nodes","ValueMeaning":{"publicId":"6741215","version":"1","preferredName":"Global Progressive Disease in Lymph Nodes","longName":"6741215","preferredDefinition":"50 percent or greater increase in the sum of products of diameter from baseline of lymph nodes; or any new node greater than 1.5 cm in the long axis or greater than 1cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically; or loss of response with greater than 50 percent increase from nadir in sum of products of diameter of lymph nodes in those with partial response (whichever occurs first).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Progressive Disease in Lymph Nodes","conceptCode":"C159961","definition":"50 percent or greater increase in the sum of products of diameter from baseline of lymph nodes; or any new node greater than 1.5 cm in the long axis or greater than 1cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically; or loss of response with greater than 50 percent increase from nadir in sum of products of diameter of lymph nodes in those with partial response (whichever occurs first).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-94D1-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8839716C-94EA-2EBA-E053-F662850AA2E9","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"PR","valueDescription":"Global Partial Response in Lymph Nodes","ValueMeaning":{"publicId":"6741216","version":"1","preferredName":"Global Partial Response in Lymph Nodes","longName":"6741216","preferredDefinition":"Cumulative reduction of 50 percent or more of the sum of products of diameter of each abnormal lymph node at baseline and no new lymph node greater than 1.5 cm in the diameter of the long axis or greater than 1.0 cm in the diameter of the short axis if the long axis is 1-1.5 cm diameter.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Partial Response in Lymph Nodes","conceptCode":"C159959","definition":"Cumulative reduction of 50 percent or more of the sum of products of diameter of each abnormal lymph node at baseline and no new lymph node greater than 1.5 cm in the diameter of the long axis or greater than 1.0 cm in the diameter of the short axis if the long axis is 1-1.5 cm diameter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-94F6-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8839716C-950F-2EBA-E053-F662850AA2E9","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Global Relapse in Lymph Nodes","ValueMeaning":{"publicId":"6741217","version":"1","preferredName":"Global Relapse in Lymph Nodes","longName":"6741217","preferredDefinition":"Any new lymph node greater than 1.5 cm in the long axis in those with complete response proven to be N3 histologically.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Relapse in Lymph Nodes","conceptCode":"C159962","definition":"Any new lymph node greater than 1.5 cm in the long axis in those with complete response proven to be N3 histologically.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-951B-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8839716C-9534-2EBA-E053-F662850AA2E9","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"},{"value":"SD","valueDescription":"Global Stable Disease in Lymph Nodes","ValueMeaning":{"publicId":"6741218","version":"1","preferredName":"Global Stable Disease in Lymph Nodes","longName":"6741218","preferredDefinition":"Fails to attain the criteria for complete response, partial response, or progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Stable Disease in Lymph Nodes","conceptCode":"C159960","definition":"Fails to attain the criteria for complete response, partial response, or progressive disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-9540-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8839716C-9559-2EBA-E053-F662850AA2E9","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6741212","version":"1","preferredName":"Global Response in Lymph Nodes Category","preferredDefinition":"Criteria for the response to treatment in lymph nodes, as a component of global response.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C159957:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Global Response in Lymph Nodes","conceptCode":"C159957","definition":"Criteria for the response to treatment in lymph nodes, as a component of global response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-9483-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"ONEDATA","dateModified":"2019-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8839716C-9494-2EBA-E053-F662850AA2E9","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"COOPERM","dateModified":"2019-05-07","changeDescription":"Created for NCI-INC0370865: 19C0076 qns curation request 4.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Response in Lymph Nodes","type":"Preferred Question Text","description":"Response in Lymph Nodes","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"883A72FE-D1E0-2F09-E053-F662850AE916","latestVersionIndicator":"Yes","beginDate":"2019-05-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-06","modifiedBy":"COOPERM","dateModified":"2019-05-08","changeDescription":"Created for NCI-INC0370865: 19C0076 qns curation request 4.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}